Related Experiment Video
Updated: Mar 19, 2026
Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis
Published on: January 2, 2017
Platelet Transfusion Outcome and Flow Cytometric Monocyte Phagocytic Assay (FMPA)
Mohammad Sayyadi1, Mojgan Shaiegan2, Mahin Nikougoftar Zarif2
1High Institute for Research and Education in Transfusion Medicine.
Background:
This study was designed to evaluate platelet transfusion outcome via flow cytometric monocyte phagocytic assay (FMPA).
Methods:
Fifteen patients with a history of multiple platelet transfusions and fifteen controls were enrolled in this study. CMFDA-labeled platelets were incubated with patients' sera and were finally incubated with monocytes in a tube and analyzed by flow cytometry. Monocytes that phagocytosed platelets were detected as a CMFDA-positive platelet population via monocyte gate. The FMPA results were compared with CCI results for the patients.
Results:
The FMPA result correlated with 1-hour (r = -0.885, P = 0.001) and 24-hour (r = -0.884, P = 0.001) CCI. There is a significant difference in means of FMPA results between the patients with immune platelet refractoriness (68.46 ± 10.4%), non-refractory group (37.73 ± 15.21%) and the control group (18.27 ± 2.86%).
Conclusion:
Our data showed that FMPA has good results in evaluation of platelet transfusion outcome and may be useful as an indicator of platelet transfusion response.
Insights
The flow cytometric monocyte phagocytic assay (FMPA) effectively evaluates platelet transfusion outcomes. This method shows strong correlation with clinical outcomes and can identify immune platelet refractoriness.
Area of Science:
- Immunology
- Hematology
- Transfusion Medicine
Background:
- Platelet transfusion outcomes require reliable evaluation methods.
- Assessing transfusion response is critical for patient care.
- Existing methods may have limitations in predicting outcomes.
Purpose of the Study:
- To evaluate the efficacy of the flow cytometric monocyte phagocytic assay (FMPA) in assessing platelet transfusion outcomes.
- To compare FMPA results with clinical indicators of platelet transfusion response.
Main Methods:
- CMFDA-labeled platelets were incubated with patient sera and monocytes.
- Flow cytometry was used to detect CMFDA-positive monocytes indicating phagocytosis.
- FMPA results were compared with the corrected count increment (CCI) in patients with a history of multiple platelet transfusions.
Main Results:
- FMPA results showed a strong negative correlation with 1-hour and 24-hour CCI (r = -0.885 and r = -0.884, respectively).
- Significant differences in FMPA means were observed between patients with immune platelet refractoriness, non-refractory patients, and controls.
- The assay effectively distinguished between groups with varying transfusion responses.
Conclusions:
- FMPA demonstrates strong performance in evaluating platelet transfusion outcomes.
- FMPA may serve as a valuable indicator for predicting platelet transfusion response.
- This assay offers a promising tool for assessing transfusion efficacy in clinical settings.
